Additionally, the 36-month beta value for CGEM is 0.01. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CGEM is 23.06M and currently, short sellers hold a 7.28% ratio of that float. The average trading volume of CGEM on May 09, 2024 was 704.77K shares.
CGEM) stock’s latest price update
The stock of Cullinan Therapeutics Inc (NASDAQ: CGEM) has decreased by -5.55 when compared to last closing price of 29.35. Despite this, the company has experienced a -1.35% fall in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-04-24 that CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31-June 4, 2024. The data will include first results from the dose escalation cohort of CLN-619 in combination with checkpoint inhibitor pembrolizumab and updated results from the monotherapy dose escalation cohort in patients with advanced solid tumors.
CGEM’s Market Performance
Cullinan Therapeutics Inc (CGEM) has experienced a -1.35% fall in stock performance for the past week, with a 62.77% rise in the past month, and a 52.06% rise in the past quarter. The volatility ratio for the week is 6.06%, and the volatility levels for the past 30 days are at 10.33% for CGEM. The simple moving average for the past 20 days is 29.47% for CGEM’s stock, with a 117.11% simple moving average for the past 200 days.
Analysts’ Opinion of CGEM
Many brokerage firms have already submitted their reports for CGEM stocks, with Stifel repeating the rating for CGEM by listing it as a “Buy.” The predicted price for CGEM in the upcoming period, according to Stifel is $40 based on the research report published on May 01, 2024 of the current year 2024.
Wedbush gave a rating of “Outperform” to CGEM, setting the target price at $30 in the report published on February 15th of the current year.
CGEM Trading at 47.65% from the 50-Day Moving Average
After a stumble in the market that brought CGEM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.18% of loss for the given period.
Volatility was left at 10.33%, however, over the last 30 days, the volatility rate increased by 6.06%, as shares surge +62.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +54.17% upper at present.
During the last 5 trading sessions, CGEM fell by -1.35%, which changed the moving average for the period of 200-days by +168.60% in comparison to the 20-day moving average, which settled at $21.94. In addition, Cullinan Therapeutics Inc saw 172.03% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CGEM starting from Michaelson Jennifer, who sale 5,606 shares at the price of $30.06 back on May 07 ’24. After this action, Michaelson Jennifer now owns 129,582 shares of Cullinan Therapeutics Inc, valued at $168,516 using the latest closing price.
Michaelson Jennifer, the Chief Scientific Officer of Cullinan Therapeutics Inc, sale 58,000 shares at $28.07 during a trade that took place back on May 06 ’24, which means that Michaelson Jennifer is holding 129,582 shares at $1,628,159 based on the most recent closing price.
Stock Fundamentals for CGEM
The total capital return value is set at -0.42. Equity return is now at value -30.98, with -29.28 for asset returns.
Based on Cullinan Therapeutics Inc (CGEM), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -37.4. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 41.41.
Currently, EBITDA for the company is -190.34 million with net debt to EBITDA at 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.07.
Conclusion
In conclusion, Cullinan Therapeutics Inc (CGEM) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
